Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials

Affiliations

• ¹ The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.
• ² Medical Research Council Population Health Research Unit at the University of Oxford, Nuffield Department of Population Health (NDPH), University of Oxford, UK.
• ³ Clinical Trial Service Unit and Epidemiologic Studies Unit (CTSU), NDPH, University of Oxford, UK.
• ⁴ Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
• ⁵ Indiana University School of Medicine and VA Medical Center, Indianapolis, IN, USA.
• ⁶ School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK.
• ⁷ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
• ⁸ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
• ⁹ NHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia.
• ¹⁰ Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
• ¹¹ Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA.
• ¹² Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia.
• ¹³ Department of Renal Medicine, University College London, London, UK.
• ¹⁴ Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, CA, USA.
• ¹⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
• ¹⁶ Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.